Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study

作者：Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao‐Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, T. Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Atsukawa, Kazuhiro Takahashi, Kunihiko Tsuji, Ei Itobayashi, Koichi Takaguchi, Pei‐Chien Tsai, Chia-Yen Dai, Jee‐Fu Huang, Chung‐Feng Huang, Ming-Lun Yeh, Eileen L. Yoon, Sung Eun Kim, Sang Bong Ahn, Gi‐Ae Kim, Jang Han Jung, Soung Won Jeong, Hyunwoo Oh, Cheng‐Hao Tseng, Masatoshi Ishigami, Angela Chau, Tiffany Hsiao, Mayumi Maeda, Satoshi Yasuda, Makoto Chuma, Takanori Ito, Keigo Kawashima, Joanne Kimiko Liu, Adrián Gadano, Ritsuzo Kozuka, Norio Itokawa, Kaori Inoue, Tomonori Senoh, Jie Li, Wan‐Long Chuang, Ramsey Cheung, Chao Wu, Ming‐Lung Yu, Mindie H. Nguyen · 发表于：EClinicalMedicine · 年份：2025 · DOI：10.1016/j.eclinm.2025.103407 · 被引用次数：3 · 研究领域：Hepatitis C virus research、Hepatitis B Virus Studies、Liver Disease Diagnosis and Treatment

Background: Metabolic dysfunction is associated with liver disease but it is unclear if it would impact responses to antiviral treatment in chronic hepatitis B (CHB) patients. Methods: Using data from an international consortium of 4507 treatment-naïve CHB patients who initiated nucleos(t)ide analogues (NAs) between January 2004 and August 2024 from 32 centers and propensity-score matching (PSM) to balance the background of patients with and without metabolic disease (diabetes, obesity, dyslipidemia, or hypertension), we compared their biochemical (BR), virologic (VR), and complete (CR) response. Findings: < 0.001). Interpretation: The presence and number of metabolic diseases were significantly and incrementally associated with lower BR. Metabolic disease should be taken into consideration in the management of CHB patients receiving NAs treatment. Funding: None.